Relay Therapeutics, Inc.
RLAYCIK 0001812364 · last filing Jul 8, 2026
Insider signal
trades dated in the last 90 days · non-derivative only
6,112 bought / 124,576 sold
net −118,464 sh · −$2.35M
- buys
- 2
- sells
- 4
- insiders active
- 4
Filing tape
Filed Wed, Jul 8, 2026
- −8,660 sh · $162.0K
Bergstrom Donald A — President, R&D
- Sold8,660Common Stock@ $18.71→ 409,897 held
- −45,143 sh · $922.5K
Patel Sanjiv — President and CEO · Director
- Granted3,056Common Stock@ $6.95→ 664,097 heldtrade dated Jun 30, 2026
- Sold48,199Common Stock@ $19.58→ 615,898 held
- −17,717 sh · $331.1K
Catinazzo Thomas — Chief Financial Officer
- Sold17,717Common Stock@ $18.69→ 159,744 held
Filed Thu, Jul 2, 2026
- −46,944 sh · $933.3K
Rahmer Peter — See remarks
- Sold50,000Common Stock@ $19.09→ 225,857 held
- Granted3,056Common Stock@ $6.95→ 228,913 held
Insiders on this tape
- Bergstrom Donald APresident, R&D
- Patel SanjivPresident and CEO · Director
- Catinazzo ThomasChief Financial Officer
- Rahmer PeterSee remarks
Informational data only — not investment advice.
The institutional holdings shown here are aggregated from third-party public regulatory filings (such as SEC Form 13F). These filings are reported with a delay (generally up to 45 days after each quarter-end), are backward-looking, and may exclude short positions, non-U.S. holdings, cash, and other assets. The data may contain errors, omissions, misclassifications, or gaps, and may not reflect a manager's current positions.
All figures are provided on an "as is" basis for general information only. Nothing on this page is financial, investment, or trading advice, a recommendation, or an endorsement of any security, manager, or strategy. Do not rely on it. Independently verify any figure against the original filings and consult a qualified professional before making any financial decision. Your use is subject to our Terms of Service.